Korro Bio, Inc.
No enriched coverage for $KRRO in the last 7 days.
No SEC Form 4 filings for $KRRO in the last 30 days.
Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, has purchased 520 shares of Korro Bio, Inc. (KRRO) common stock at $10.60 per share, as reported in a recent SEC Form 4 filing. This transaction brings their indirect holdings to 1,538,296 shares. Both Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership except for any pecuniary interest.
Korro Bio reported a widening net loss in 2025 to $117.3 million, up from $83.6 million in 2024, despite an increase in collaboration revenue and progress in its RNA-editing pipeline. The company nominated KRRO-121 as a development candidate for hyperammonemia and advanced its alpha-1 antitrypsin deficiency program. An $85 million private placement in March 2026 is expected to extend Korro Bio's cash runway into the second half of 2028.
Korro Bio, Inc. announced that its CEO, Dr. Ram Aiyar, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:10 a.m. ET. The biopharmaceutical company focuses on developing genetic medicines through RNA editing for rare and common diseases. This presentation aims to highlight Korro Bio's innovative approach and proprietary technology to investors and industry professionals.
